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INTRODUCTION:  Neuroendocrine  tumors  of the  colon  and rectum  are  relatively  rare  compared  to  sporadic
colorectal carcinoma.  There  are  few reports  of neuroendocrine  tumors  of  the  colon  and  rectum  in patients
with ulcerative  colitis.
PRESENTATION  OF  CASE:  A  patient  with  sigmoid  colon  carcinoma  with  focal  neuroendocrine  features  is
presented.  A  32-year-old  man,  who  had  been  followed  for ulcerative  colitis  for  14  years,  was  found  to
have  carcinoma  of the  sigmoid  colon  on routine  annual  colonoscopy,  and  he  underwent  laparoscopic  total
colectomy.  Pathologic  examination  showed  sigmoid  colon  adenocarcinoma  with  focal  neuroendocrinelcerative colitis
olorectal cancer
ase report
features.
DISCUSSION:  Most  colorectal  carcinomas  associated  with  inﬂammatory  bowel  disease  are  histologically
similar  to the  sporadic  type,  and tumors  with  neuroendocrine  features  are very  unusual.
CONCLUSION:  Very  rare  case  of  sigmoid  colon  carcinoma  with  neuroendocrine  features  arising  in  a  patient
with UC  was  described.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Background
It is widely accepted that patients with ulcerative colitis have an
ncreased risk of developing colorectal cancer. If epithelial dysplasia
r carcinoma is diagnosed on surveillance colonoscopy, experts rec-
mmend elective colectomy [1]. The rates of malignant lymphoma
nd sarcoma have also been reported to be higher in patients with
nﬂammatory diseases, although the etiology is not fully under-
tood. A patient with a 14-year history of ulcerative colitis found to
ave sigmoid colon carcinoma with focal neuroendocrine differen-
iation is described. Neuroendocrine tumors (NET) in patients with
C have rarely been reported [2]. A literature review of previously
eported patients is also presented.
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ttp://dx.doi.org/10.1016/j.ijscr.2016.04.035
210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/).2. Presentation of case
A 32-year-old male patient with a 14-year history of ulcera-
tive colitis (UC), total colitis type, was followed at another hospital.
The patient underwent steroid therapy for about two  years, and
stopped three years ago. Only 5-ASA was administered as mainte-
nance therapy, and he was symptom-free for the last three years.
On annual colonoscopy, a slightly elevated 2-cm lesion with
small central ulcer was  seen in the sigmoid colon (Fig. 1). The
surface of the lesion was irregular and the margin was  unclear.
The surrounding colonic mucosa was  pale and rough, suggesting
a quiescent phase of UC activity. Biopsies of the lesion showed
well-differentiated tubular adenocarcinoma. Computed tomogra-
phy (CT) showed partial wall thickening of the sigmoid colon
with no lymphadenopathy or distant metastases. Laboratory data
were normal, and tumor markers were not elevated. He was  diag-
nosed with sigmoid colon carcinoma associated with UC, and
laparoscopic-assisted total colectomy with an ileal pouch-anal
anastomosis was  performed. The patients’ postoperative course
was uneventful.The histopathology of the specimen revealed a tubular adeno-
carcinoma invading to the muscularis propria (pMP) with focal
neuroendocrine differentiation (Fig. 2a). Neuroendocrine features
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
CASE  REPORT  –  OPEN  ACCESS
152 K. Rifu et al. / International Journal of Surgery Case Reports 23 (2016) 151–156
 Type
w
s
p
5
t
i
c
t
w
s
b
a
t
c
n
3
c
d
c
b
i
p
t
a
w
r
T
h
d
n
n
a
i
t
a
o
o
U
p
dFig. 1. Colonoscopic image of a
ere found in the marginal area of the tumor, (Figs. 2 b, 3 a) which
tained positive for both Chromogranin A (Fig. 3b) and Synapto-
hysin (Fig. 3c) and negative for CD56 (Fig. 3d), Ki67 index was
0%. The mucosa from the sigmoid colon to the rectum appeared
o be atrophic, macroscopically. There were ﬁbrotic changes with
ncreased lymphoid follicles in the submucosal layer microscopi-
ally, suggesting a long history of chronic inﬂammation secondary
o UC. The malignant tumor in the sigmoid colon was  consistent
ith a tumor arising from chronically inﬂamed colonic mucosa
econdary to UC. Two of 15 regional lymph nodes were found to
e positive (adenocarcinoma, pN1), and the lesion was diagnosed
s stage IIIa according to the general rules of Japanese classiﬁca-
ion of colorectal carcinoma [3]. Capecitabine was given as adjuvant
hemotherapy for six months. At three years follow-up, there was
o evidence of recurrent disease.
. Discussion
Patients with UC are at increased risk for developing colorectal
arcinoma and dysplasia. The extent of colitis and duration of the
isease are the most important risk factors for the development of
olorectal carcinoma [4].
However, patients with NET associated with inﬂammatory
owel disease have rarely been reported [2,5]. A literature search
ncluding papers published from 1980 to 2015 showed only 13
atients with NET associated with UC (Table 1). Patients in whom
he carcinoid tumor was not directly associated with a dysplasia-
ssociated lesion or mass or adenocarcinoma in UC (colitic cancer)
ere excluded, because carcinoid tumors can be diagnosed spo-
adically. Most patients had a long history of UC (median 15 years).
en of 13 lesions were found in the recto-sigmoid, and ﬁve patients
ad distant metastases at the time of diagnosis. Three patients
ied from the disease within 15 months, although eight reports did
ot mention the outcome. These ﬁndings suggest a higher malig-
ant potential of the disease compared to typical colitic carcinoma
ssociated with UC. Risk factors are the same as colitic carcinoma
ncluding a long duration of mucosal inﬂammation and pan-colitis
ype of UC.
Dysplasia-associated lesions or masses (DALM) are elevated
reas known to have an increased risk for the development
f adenocarcinoma in UC. DALMs and inﬂammatory polyps are
ccasionally seen on surveillance colonoscopy in patients with
C [4,13]. A DALM does not appear like a typical adenomatous
olyp, but often has a different appearance such as ﬂat, granular,
epressed and others [13]. In contrast, neuroendocrine tumors of 3 tumor of the sigmoid colon.
the colon and rectum usually appear as a submucosal tumor in the
early stages [14], and as type 2 or type 3 lesions in advanced stages.
In this patient, the tumor showed a slightly elevated lesion with
small central ulcer, and the margin was unclear. These ﬁnding were
unusual for sporadic colorectal carcinoma.
Based on the 2010 World Health Organization classiﬁcation, NET
is stratiﬁed into two  types, neuroendocrine carcinoma and mixed
adeno-neuroendocrine carcinoma (MANEC), according to the pro-
portion of neuroendocrine cells and adenocarcinoma cells. MANEC
is deﬁned as a lesion with more than 30% neuroendocrine cells.
In this patient, the proportion of cells with neuroendocrine fea-
tures was less than 30%, meaning a diagnosis of NET (or colorectal
carcinoma with focal neuroendocrine feature), not MANEC [15].
As for NET in the gastrointestinal tract, cisplatin/etoposide is
a standard chemotherapy regimen [16]. However, most NETs in
the colon and rectum were MANEC in our previous study [17].
MANEC has a greater component of adenocarcinoma elements,
and the efﬁcacies of both Irinotecan/Cisplatin and 5-Fﬂuorouracil
based chemotherapy have been reported for some patients with
MANEC [17]. Adjuvant chemotherapy for patients with MANEC
should also be considered because some reports indicated its effec-
tiveness [17,18]. In the present patient, all metastatic lymph nodes
appeared to be adenocarcinoma, and capesitabine was given as
adjuvant therapy for six months. He has been free of recurrence
for three years. It is not yet clear which chemotherapy regimen is
most effective in patients with MANEC (or colorectal cancer with
neuroendocrine features), because few cases have been reported.
Although colorectal carcinomas are the most frequent tumors
found in patients with IBD, other types of tumors have been asso-
ciated with inﬂammatory bowel disease, such as lymphoma and
sarcoma. One hypothesis is that chronic inﬂammation of the colonic
mucosa may  cause pancellular damage involving epithelial, goblet,
Paneth and neuroendocrine cells, resulting in pancellular dysplasia
[5]. It has been also hypothesized that the development of neuroen-
docrine tumors may  be secondary to distant secretion of cytokines
(transforming growth factor alpha, proinﬂammatory cytokines,
interferon gamma, tumor necrosis factor alpha, and interleukins)
[19]. The combination of both inﬂammation −related pancellular
dysplasia and secretion of systemic mediators may  partially explain
the development of neuroendocrine tumors in IBD patients. Serum
Chromogranin A has been reported to be elevated in patients with
advanced disease and those who  have elevated at diagnosis. Fol-
lowing serum Chromogranin A levels in patients with advanced
neuroendocrine tumors is recommended by the North American
Neuroendocrine Tumor Society (NANETS) [20].
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Table 1
Previously reported patients with NET associated with UC.
Patient Age(y)/Gender Duration (y) Extent Indication Status Site Differentiation Depth of
invasion
Dysplasia Metastases Refs.
1 67/M 50 Limited colitis Dysplasia NED; 14
months
Rectum Carcinoid Submucosa Adjacent HGD NK [2]
2 44/M 15 Pancolitis AdenoCa DOD; 11
months
Rectum Mixed Transmural Adjacent HGD NK [2]
3 52/M 10 Pancolitis Dysplasia NK Sigmoid Colon Mixed Muscularis
propria
Adjacent and
distant HGD
NK [2]
4 35/M 11 Mild distal colitis NET DOD; 15
months
Rectum Large cell NEC NK NK NK [5]
5 77/M 27 Left sided colitis NET NK Anorectal junction Small cell NEC Unknown NK NK [5]
6 32/M 15 Pancolitis NK NK Spleen Mixed Unknown NK Yes [6]
7 56/M 26 Pancolitis Stricture DOD; 10
months
Sigmoid Colon Small cell NEC Unknown None Yes [7]
8 55/M 42 Not stated NK NK Rectal stump Atypical carcinoid Unknown Adjacent HGD
and mulitifocal
LGD
NK [8]
9 66/F 26 Pancolitis NK NK Rectum Adenocarcinoid Unknown Adjacent and
distant
Yes [9]
10 50/M 0 NK NK NK Rectum (multifocal) Carcinoid NK Multifocal HGD NK [10]
11 25/F 13 NK NK NK Splenic Atypical NK Multiple foci Yes [11]
12 32/M 16 Pancolitis NK NK Cecum (multifocal) “Malignant” carcinoid unknown NK Yes [12]
13 32/M 14 Pancolitis AdenoCa NED; 36
months
Sigmoid Colon mixed MP  Adjacent HGD NK Present patient
AdenoCa: Adenocarcinoma. DOD: Dead of Disease. F: Female. HGD: High Grade Dysplasia. LGD: Low Grade Dysplasia. M:  Male. NED: No Evidence of Disease. NET: Neuroendocrine Tumor. NK: Not Known/Not Reported.
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F e is the
( e (Fig.
4
dig. 2. (a) Gross pathology of a resected Type 3 tumor of the sigmoid colon. Black lin
H&E,  1.25×) Focal neuroendocrine features was seen in the area of the black squar. Conclusion
A very rare case of sigmoid colon carcinoma with neuroen-
ocrine features arising in a patient with UC was described. section b. (b) Microscopic image of the section with focal neuroendocrine features.
 3a–d).Evaluation of more patients is needed to deﬁne an optimal treat-
ment strategy for patients with this disease.
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tain  in the area of focal neuroendocrine features (4×). (d) CD56 stain in the area of
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